{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:15:34Z","timestamp":1768803334388,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Osimertinib combined with chest radiotherapy has a high incidence of pneumonia, dacomitinib is widely used in clinical practice, but there are no studies reporting the pulmonary safety of dacomitinib in combinating with radiotherapy. Here we report a case of radiation pneumonitis occurring by dacomitinib and thoracic radiotherapy (TRT). The patient was a 55-year-old woman with lung adenocarcinoma. She had received surgery and adjuvant chemotherapy. The patient presented with bilateral intramammary and para-aortic metastatic lymphadenopathy, which was confirmed as metastasis, and subsequently received treatment with dacomitinib. Radiotherapy started after 4 months of dacomitinib. The Clinical Target Volume (CTV) was metastatic lymph nodes area. The prescription dose was 60 Gy\/30F. The mean lung dose (MLD), V20, and V5 were 8.16Gy, 16%, and 34.5%. Despite the lung V20 and mean lung dose being exceptionally low, the patient exhibited respiratory symptoms, and a CT chest scan revealed grade 4 radiation pneumonitis two weeks following the conclusion of radiotherapy. The radiotherapy and dacomitinib were discontinued, and immediate initiation of pulmonary anti-inflammatory treatment ensued. The concurrent administration of dacomitinib and RT carries the risk of inducing serious pneumonia. This case highlights the potential risk of severe pneumonia associated with this combination therapy, emphasizing the need for further research to clarify its safety and develop effective management strategies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1436134","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:10:44Z","timestamp":1740460244000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Ailing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaikai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation doseation.R effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314","article-title":"Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of egfr mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of egfr mutation-positive nonation-posit lung cancer: A clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jncc.2022.11.003","article-title":"Real-world treatment patterns and practices clinical outcomes in egfr-mutant locally advanced lung adenocarcinoma: A multi-center cohort study","volume":"3","author":"Bi","year":"2023","journal-title":"J Natl Cancer Center"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic egfr-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S404874","article-title":"Comparison of the incidence rate of radiation pneumonitis observed in patients with advanced lung adenocarcinoma treated with simultaneous thoracic radiotherapy and 1g\/2g\/3g egfr-tkis","volume":"15","author":"Mu","year":"2023","journal-title":"Cancer Manage Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12885-024-11946-y","article-title":"Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in egfr-mutant non-small cell lung cancer patients","volume":"24","author":"Yin","year":"2024","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.radonc.2020.07.051","article-title":"An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib","volume":"152","author":"Jia","year":"2020","journal-title":"Radiother Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.025","article-title":"Safety and efficacy of first-line dacomitinib in asian patients with egfr mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (Archer 1050)","volume":"154","author":"Cheng","year":"2021","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with egfr-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: A multicenter, randomized, controlled, phase iii trial","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and egfr-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.026","article-title":"Erlotinib versus etoposide\/cisplatin with radiation therapy in unresectable stage iii epidermal growth factor receptor mutation-positive non-small cell lung cancer: A multicenter, randomized, open-label, phase 2 trial","volume":"109","author":"Xing","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic nsclc harboring egfr activating mutation treated with first-line egfr-tkis","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.019","article-title":"Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced nsclc with egfr mutation; west Japan oncology group 6911l","volume":"16","author":"Akamatsu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13816","article-title":"Clinical outcomes and radiation pneumonitis after concurrent egfr-gfrurren kinase inhibitors and radiotherapy for unresectable stage iii nongeecta cell lung cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Thorac Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1634\/theoncologist.2019-0285","article-title":"Concurrent egfr-tki and thoracic radiotherapy as first-line treatment for stage iv non-small cell lung cancer harboring egfr active mutations","volume":"24","author":"Zheng","year":"2019","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-696","article-title":"Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment\u2013case report","volume":"10","author":"Hsieh","year":"2010","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000126","article-title":"Radiation pneumonitis in patients with non\u2013small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy","volume":"9","author":"Zhuang","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100468","article-title":"Brief report: severe pneumonitis after combined thoracic radiotherapy and osimertinib","volume":"4","author":"Smith","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of egfr: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase ii study (Archer 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from egfr tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced egfr-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with egfr tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of egfr-tki pneumonitis in nsclc","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14384","article-title":"Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer","volume":"111","author":"Nishio","year":"2020","journal-title":"Cancer Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13816","article-title":"Clinical outcomes and radiation pneumonitis after concurrent egfr-tyrosine kinase inhibitors and radiotherapy for unresectable stage iii non-small cell lung cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Thorac Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"Egfr signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.3390\/ijms20164021","article-title":"Blockade of egfr activation promotes tnf-induced lung epithelial cell apoptosis and pulmonary injury","volume":"20","author":"Yamaoka","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-108","article-title":"Exploration of radiation-induced lung injury, from mechanism to treatment: A narrative review","volume":"11","author":"Yan","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S62707","article-title":"Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy","volume":"7","author":"Zhuang","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2016.06.019","article-title":"Imaging after radiation therapy of thoracic tumors","volume":"97","author":"Ghaye","year":"2016","journal-title":"Diagn Interv Imaging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"107822","DOI":"10.1016\/j.lungcan.2024.107822","article-title":"Optimal management of radiation pneumonitis: findings of an international delphi consensus study","volume":"192","author":"Voruganti Maddali","year":"2024","journal-title":"Lung Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2022.07.003","article-title":"Use of glucocorticoids in patients with cancer: potential benefits, harms, and practical considerations for clinical practice","volume":"13","author":"Kim","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: assessment and management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2016.12.004","article-title":"Radiation pneumonitis","volume":"38","author":"Bledsoe","year":"2017","journal-title":"Clinics Chest Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.02.030","article-title":"Randomized phase 2 placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis","volume":"116","author":"Rimner","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13014-021-01765-x","article-title":"Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous egfr-tki and thoracic radiotherapy","volume":"16","author":"Jia","year":"2021","journal-title":"Radiat Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109681","article-title":"Egfr-tkis plus stereotactic body radiation therapy (Sbrt) for stage iv non-small cell lung cancer (Nsclc): A prospective, multicenter, randomized, controlled phase ii study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1436134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:10:49Z","timestamp":1740460249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1436134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":41,"alternative-id":["10.3389\/fonc.2025.1436134"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1436134","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1436134"}}